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OBJECTIVES We investigated whether abnormal pteridine metabolism is related to coronary endothelial
dysfunction in insulin-resistant subjects.
BACKGROUND Depletion of tetrahydrobiopterin (BH4) and elevation of the 7,8-dihydrobiopterin (BH2)
(activating and inactivating cofactors of nitric oxide synthase [NOS], respectively) contribute
to impairment of NO-dependent vasodilation through reduction of NOS activity as well as
increased superoxide anion generation in insulin-resistant rats.
METHODS Thirty-six consecutive nondiabetic, normotensive and nonobese subjects with angiographi-
cally normal coronary vessels were studied. Traditional coronary risk factors, plasma pteridine
levels, activities of erythrocyte dihydropteridine reductase (DHPR), the recycling enzyme that
converts BH2 to BH4 and lipid peroxide (LPO) levels were measured and coronary
endothelial function was assessed with graded infusions of acetylcholine (ACh).
RESULTS When we divided patients into tertiles based on insulin sensitivity, we observed stepwise
decreases in the maximal ACh-induced vasodilation and plasma BH4/7,8-BH2 ratio, and
increases in coronary LPO production as insulin sensitivity decreased. The ACh-induced
vasodilation was positively correlated with insulin sensitivity, BH4/7,8-BH2 ratio and DHPR
activity. Furthermore, BH4/7,8-BH2 was inversely correlated with DHPR activity and insulin
sensitivity. In multiple stepwise regression analysis, BH4/BH2 was independently related to
ACh-induced vasodilation and accounted for 39% of the variance. However, no significant
correlation existed between other traditional risk factors and BH4/7,8-BH2.
CONCLUSIONS These results indicate that both abnormal pteridine metabolism and vascular oxidative stress
are linked to coronary endothelial dysfunction in the insulin-resistant subjects. (J Am Coll
Cardiol 2001;38:1821–8) © 2001 by the American College of Cardiology
Because defects of endothelium-dependent vascular reactiv-
ity are fundamental pathologic abnormalities in various
insulin-resistant states such as diabetes, obesity, hyperten-
sion, and aging, endothelial damage has been implicated in
preceding and likely contributing to the development of
cardiovascular disease in these states (1–3). Recent clinical
evidence has shown a possible link between diminished
coronary vasodilator response to acetylcholine (ACh) and
hyperinsulinemia in patients with vasospastic angina (4,5).
In contrast, the response of coronary blood flow to NG-
monomethyl-L-arginine, a competitive inhibitor of nitric
oxide synthase (NOS), was reduced in patients with vaso-
spastic angina, and antioxidant treatment restored endothe-
lial function in these patients (5,6). These results led to the
proposal that impairment of insulin action on the endothe-
lial nitric oxide (NO) system could contribute to the
derangement of NO production/action in these states
(1,2,7). However, the factors contributing to NO-mediated
endothelial dysfunction in human insulin-resistant state are
not fully defined.
There is increasing experimental evidence that (6R)-
5,6,7,8-tetrahydrobiopterin (BH4), the natural and essential
cofactor of NOS, plays a crucial role not only in increasing
the rate of NO generation by NOS but also in controlling
the formation of superoxide anion (O2
) in endothelial cells
(8). The biosynthesis of intracellular BH4 is governed by
two enzymes: GTP cyclohydrolase I (GTP-CH1), which
regulates its rate of formation, and dihydropteridine reduc-
tase (DHPR), which regulates its rate of regeneration.
Utilization of BH4 in NO synthesis generates quinonoid
dihydrobiopterin rather than dihydrobiopterin (BH2) (8,9).
Alternatively, quinonoid BH2 may rearrange nonenzymat-
ically to BH2, which is no longer a substrate for DHPR
(10). To maintain BH4, increases in both enzyme activities
are crucial. We have recently reported that under insulin-
resistant conditions where the BH4 levels are in a subnormal
range, the excessive production of O2
 by NO synthase may
lead to hydroxyl radical production and oxidative tissue
damage (11). This hypothesis was supported by the finding
that long-term activation of endothelial NOS (eNOS) by
oral administration of BH4 prevents endothelial dysfunction
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and vascular oxidative stress in the aortas of insulin-resistant
rats (12).
Therefore, we examined the effect of insulin resistance on
in vivo pteridine metabolism and endothelial dysfunction,
which we evaluated by analyzing graded degrees of ACh-
induced vasoconstriction in subjects with angiographically
normal coronary arteries.
METHODS
Study subjects. Forty-four subjects were selected from
consecutive patients who entered Osaka Police Hospital
between 1998 and 2000 for coronary angiography because of
atypical chest pain that occurred predominantly at rest, or
for clinically suspected coronary vasospastic angina. Eight
subjects initially evaluated were disqualified because of the
presence of obstructive coronary artery disease (n  3) or
diabetes (n  5). All blood specimens were taken after a
12-h fast, with no interruption of drug treatment. Patients
who were taking lipid-lowering drugs, beta-adrenergic
blocking drugs or diuretics, which might have adverse effects
on carbohydrate and lipid metabolism, were excluded from
the study. Patients with a history of hypertension, obesity
(body-mass index 26 kg/m2) or diabetes mellitus, and
who were known to have impaired insulin sensitivity and
endothelial dysfunction (13–15), were excluded from the
study. Subjects with hypercholesterolemia (total cholesterol
6.2 mmol/l), myocardial infarction, unstable angina, val-
vular disease, hepatic, renal or endocrine dysfunction were
also excluded. Finally, a total of 36 nondiabetic, normoten-
sive and nonobese subjects (24 men, 12 women) with
angiographically normal coronary vessels (25% stenosis
of the luminal diameter) fulfilled the criteria for participa-
tion in this study. All subjects gave their written informed
consent, and the study protocol was approved by the Ethics
Committee of the Osaka Police Hospital.
Baseline investigation. One day before cardiac catheter-
ization, venous blood samples were drawn from each subject
after an overnight fast for measurements of plasma glucose,
insulin, total cholesterol, triglyceride and high-density li-
poprotein cholesterol. A 75-g load of oral glucose (Trelan G
75, Shimizu, Shizuoka) was administered, and blood sam-
ples were drawn at 30, 60 and 120 min for determination of
plasma glucose and insulin concentrations. Plasma glucose
and insulin responses to glucose ingestion were evaluated by
calculation of the areas under the curves of glucose and
insulin throughout the 120 min of the test period. The
definition of glucose tolerance was based on a 2-h oral
glucose tolerance test (OGTT) according to the criteria of
the American Diabetes Association (16). Hypertension was
defined as systolic blood pressure 140 mm Hg and/or
diastolic blood pressure 90 mm Hg. As a cumulative
estimate of tobacco consumption, cigarette-years (pieces/
day  years) was used.
Coronary angiography. Coronary angiography was per-
formed by the Judkins technique using a biplane cinean-
giography system in the morning when the patients were
fasting (17). Thirty subjects (83.3%) had completely normal
coronary arteries, and those of the others were nearly normal
(25% stenosis). Incremental doses of ACh (50 g,
100 g) were injected into the left main coronary artery
through the catheter. Coronary spasm was defined as total
or subtotal (a change in diameter 75%) vessel occlusion
associated with chest pain or ischemic ST changes on the
electrocardiogram or both. After the completion of the
intracoronary injection of ACh, when the systemic hemo-
dynamic parameters and the coronary arterial diameter on
angiograms had returned to the baseline levels, 300 g of
nitroglycerin (NTG) was injected into the coronary artery,
and coronary angiography was performed in multiple pro-
jections. The luminal diameter at the center of the left
anterior descending artery was measured quantitatively with
the use of a computer-assisted coronary angiographic anal-
ysis system (GE Medical Systems, Milwaukee, Wisconsin)
by two observers blinded to the clinical history and risk-
factor profile (18). Responses of coronary artery diameter to
infusion of ACh and NTG were expressed as percentage
changes from the baseline coronary diameter (i.e., 100 
[diameter after ACh or NTG baseline diameter]/baseline
diameter).
Blood sampling. Blood samples were collected simulta-
neously from the coronary sinus (CS) and descending aorta
(Ao) 1 min before and 1 min after ACh injection at the
same speed and were placed on ice immediately after
collection. A 10-ml blood sample was drawn into an
ethylenediamine tetraacetate vacutainer and centrifuged at
3,000 rpm for 15 min at 4°C. After plasma was separated
and the buffy coat was removed, erythrocytes were sus-
pended in phosphate-buffered saline and centrifuged again.
Thus, obtained packed erythrocytes and the separated
Abbreviations and Acronyms
ACh  acetylcholine
Ao  descending aorta
BH2  7,8-dihydrobiopterin
BH4  (6R)-5,6,7,8-tetrahydrobiopterin
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DHPR  dihydropteridine reductase
eNOS  endothelial nitric oxide synthase
GTP-CH1  GTP cyclohydrolase I
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LPO  lipid peroxide
NO  nitric oxide
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plasma were stored at 80°C until use. Coronary lipid
peroxide (LPO) production during ACh infusion was cal-
culated by the formula: CS  Ao difference  (thiobarbi-
turic acid reactive substances [TBARS] level after ACh in
the CS  that in the Ao) minus (TBARS level before ACh
in the CS  that in the Ao). Plasma concentrations of
biopterin derivative and total radical-trapping antioxidant
parameter (TRAP) and erythrocyte DHPR activity were
not significantly different between the CS and Ao regardless
of ACh injection. Therefore, the levels of these variables
were measured in the samples collected from the CS before
ACh injection.
Plasma biopterin derivative levels and DHPR activities.
Plasma biopterin levels were measured by high-performance
liquid chromatography as previously described (11,12). The
amount of BH4 was estimated from the difference between
the total (BH4  7,8-BH2  oxidized biopterin) and
alkaline-stable biopterin (7,8-BH2  oxidized biopterin).
The DHPR, the recycling enzyme to convert BH2 to BH4,
was assayed by the method of Arai et al. (19).
Measurement of LPO content and TRAP. Plasma
TBARS content was measured by the fluorometric method
described previously (20). Plasma antioxidant defenses were
evaluated by measuring the TRAP (21).
Statistical analysis. All values are presented as means 
SE. All analyses were performed using a personal computer
with the statistical software package SPSS, version 6.0.
Group differences of categorical data were tested by chi-
square analysis with the Yates’ correction. The plasma
glucose and insulin responses in the three groups during
OGTT, blood pressure and lipid concentrations were com-
pared using analysis of variance with a post hoc Scheffe´
comparison. The dose-dependent vascular responses were
compared among the three groups using repeated-measures
analysis of variance. The Pearson coefficient was used for
normally distributed data, and the Spearman coefficient was
used for abnormally distributed data to assess the relation
between continuous factors. A p value  0.05 was consid-
ered statistically significant.
RESULTS
Characteristics of the study groups. According to the
tertiles of plasma insulin responses during OGTT, 12
subjects were classified as insulin resistant (IR) with 2-h
insulin area 800 pmol/l  h, 12 as insulin sensitive (IS)
with 2-h insulin area 600 pmol/l  h, and 12 as
borderline (BL) with 2-h insulin area over 600 and
800 pmol/l  h. As shown in Table 1, subjects in the
three groups were comparable with regard to age, gender,
body-mass index, proportions of glucose tolerance and
blood pressure. Both the percentage of active smokers and
cumulative tobacco consumption were significantly higher
in the IR than in the IS group. Analysis of the data from the
OGTT showed that both fasting glucose level and 2-h
glucose area were not significantly different among IS, IR
and BL subjects, whereas the IR group had higher fasting
insulin values than the other groups. There were no signif-
icant differences in plasma total cholesterol and HDL
cholesterol among these three groups despite higher triglyc-
eride concentration in IR subjects than in the other groups.
Baseline hemodynamic parameters and responses of epi-
cardial coronary diameter to ACh and NTG. Baseline
values of heart rate, mean blood pressure and left ventricular
ejection fraction were not different among the three groups.
Seven patients showed coronary spasm and 16 subjects had
completely normal coronary arteries with neither coronary
spasm (a change in diameter 50%) nor ischemic ST
change in the ACh-provocation test. As shown in Figure 1,
the constrictor responses of the epicardial coronary arteries
to ACh were dose-dependently increased in all groups. The
maximal ACh-induced coronary vasoconstriction induced
Table 1. Baseline Characteristics Categorized by Tertiles of Two-Hour Insulin Area in Patients
With Angiographically Normal Coronary Arteries and No Other Risk Factors
IS (n  12) BL (n  12) IR (n  12)
Age (yr) 61.0  1.8 55.1  3.4 54.5  3.8
Gender (male/female) 9/3 9/3 8/4
BMI (kg/m2) 22.9  0.7 23.2  1.1 23.4  0.8
Smoking (%) 33 75 83
Cigarette-years 122  62 420  124 479  126*
Glucose tolerance (NGT/IGT) 8/4 4/8 6/6
Fasting glucose (mmol/l) 5.42  0.14 5.20  0.12 5.41  0.12
2-h glucose area (mmol/l  h) 15.9  0.7 17.6  0.8 17.3  1.2
Fasting insulin (pmol/l) 47.8  7.5 46.1  7.0 67.6  8.7*‡
2-h insulin area (pmol/l  h) 452.3  30.8 730.3  17.7 1454.4  140.8†§
Total cholesterol (mmol/l) 4.86  0.24 4.98  0.17 4.97  0.26
HDL cholesterol (mmol/l) 1.57  0.11 1.58  0.18 1.41  0.12
Triglycerides (mmol/l) 0.61  0.10 0.93  0.14 1.01  0.17*
Systolic BP (mm Hg) 126.7  3.2 129.0  4.0 124.3  3.2
Diastolic BP (mm Hg) 78.5  1.6 72.8  1.9 75.2  2.7
*p  0.05. †p  0.001 vs. IS. ‡p  0.05. §p  0.001 vs. BL. Values are mean  SEM or number of patients.
BL borderline; BMI body-mass index; BP blood pressure; HDL high density lipoprotein; IGT impaired glucose
tolerance; IR  insulin resistant; IS  insulin sensitive; NGT  normal glucose tolerance.
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by injection of ACh at a dose of 100 g in IR subjects was
1.8-fold and 1.6-fold higher (p  0.05) than that in IS and
BL subjects, respectively. Conversely, no significant differ-
ence existed in the magnitude of the coronary dilator
response to NTG among the three groups.
Plasma concentrations of biopterin derivatives and
DHPR activity. To determine whether changes occurred
in the levels of pteridine metabolites as determinants of
ACh-induced coronary vasoconstriction, we measured the
plasma levels of biopterin derivatives in the three groups. No
significant difference was found among the three groups in
the absolute values of concentrations of neopterin, total
biopterin, or BH4 (Table 2). However, the plasma level of
biopterin plus 7,8-BH2, an oxidized form of BH4, in IR
subjects was 1.43-fold and 1.24-fold higher than that in IS
or BL subjects, respectively. The ratio of BH4 to 7,8-BH2
plus biopterin (BH4/7,8-BH2 ratio) as well as the ratio of
BH4 to total biopterin was significantly lower in IR subjects
than in IS or BL subjects.
Consistent with these results, IR subjects exhibited a
significant decrease in the activity of DHPR when com-
pared with the other groups. In separate analyses, plasma
levels of biopterin derivatives and erythrocyte DHPR activ-
ity in patients with vasospastic angina (VSAP) were com-
pared with those in control subjects (chest pain syndrome).
The BH4/7,8-BH2 ratio (control, 4.62  0.33; VSAP,
3.45 0.46, p 0.05) and DHPR activity (control, 3.57
0.13; VASP, 2.81  0.14 nmol nicotinamide adenine
dinucleotide/min/mg hemoglobin, p  0.01) were also
significantly reduced in patients with VSAP compared to
control subjects.
Lipid peroxidation and antioxidant system components.
The increase in the plasma levels of TBARS above the basal
value after ACh injection was slightly but not significantly
higher in IR subjects than in the other groups (IS, 2.30 
0.59; BL, 2.24 0.46; IR, 3.13 0.38 nmol/ml). In contrast,
there was a trend toward decreased plasma levels of TRAP as
insulin sensitivity decreased, and the TRAP level in IR subjects
was significantly lower than that in IS subjects (IS, 303  39;
BL, 247  27; IR, 197  32 mol/l, p  0.05).
Analyses of risk factors for endothelial dysfunction.
Univariate analysis showed that the constrictor response of
the coronary diameter to ACh (100 g) had a significant
positive correlation with the 2-h insulin area, TBARS level
(Fig. 2) and cigarette-years (r  0.36, p  0.05). Con-
versely, an inverse correlation between the response to ACh
and either BH4/7,8-BH2 ratio or DHPR activity was
observed. To exclude the possibility that angiographic
results in the spasm patients might affect the results of the
present study, these univariate analyses were carried out in
subjects without vasospasm. As a result, a similar tendency
was observed in these subjects. A 2-h insulin area as a
marker of insulin resistance was positively correlated with
7,8-BH2 plus biopterin and TBARS level, and this was
inversely correlated with BH4/7,8-BH2 ratio, BH4/total
biopterin and DHPR activity. Interestingly, lower BH4/7,8-
BH2 ratio was correlated with higher cumulative tobacco
consumption. Similarly, DHPR activity was associated with
an increase in BH4/7,8-BH2 ratio, and a decrease in
TBARS level.
Multivariate analyses using stepwise regression models were
carried out to analyze the relationships between the percent
Figure 1. Percent changes in left anterior descending artery (LAD)
diameters from baseline values in response to intracoronary infusion of
graded dose (50 g, 100 g) of acetylcholine (ACh) and to 0.3 mg of
nitroglycerin (NTG) categorized by tertiles of insulin sensitivity in patients
with normal coronary angiogram (n  36). IS  insulin sensitive (open
bars); BL  borderline (solid bars); IR  insulin resistant (hatched bars).
*p  0.05 vs. IS. †p  0.05 vs. BL.
Table 2. Concentrations of Plasma Pteridine Derivatives and Erythrocyte Dihydropteridine
Reductase Activity in the Coronary Sinus
IS
(n  12)
BL
(n  12)
IR
(n  12)
Neopterin (nmol/l) 35.5  3.2 36.7  1.7 37.5  1.8
Total biopterin (nmol/l) 42.4  2.9 44.7  2.7 44.3  3.1
BH4 (nmol/l) 34.7  2.3 35.8  2.2 33.4  3.3
7,8-BH2  biopterin (nmol/l) 7.67  0.76 8.87  0.67 11.0  0.59†‡
Neopterin/total biopterin 0.84  0.05 0.92  0.09 0.84  0.06
BH4/total biopterin 0.83  0.01 0.80  0.01 0.766  0.02†‡
BH4/7,8-BH2  biopterin 4.85  0.31 4.24  0.38 3.21  0.31†‡
DHPR activity (nmol NADH/min/mg Hb) 3.35  0.58 3.27  0.71 2.75  0.46*‡
*p  0.05. †p  0.001 vs. IS. ‡p  0.001 vs. BL.
BH2  dihydrobiopterin; BH4  tetrahydrobiopterin; BL  borderline; DHPR  dihydropteridine reductase; Hb 
hemoglobin; IR  insulin resistant; IS  insulin sensitive; NADH  nicotinamide adenine.
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changes of ACh-induced coronary diameters and a set of
variables selected on the basis of the above-cited correlation
analyses (TBARS level, BH4/7,8-BH2 ratio, and DHPR
activity) and other recognized risk factors. As shown in Table
3, BH4/7,8-BH2 ratio and DHPR activity were independently
associated with the constrictor response to ACh and explained
12% to 25% of the variation in the response to ACh. Cigarette-
years, which showed positive correlation with response to ACh
in univariate analyses, did not show any substantial correlation
in multivariate analyses.
Figure 2. Correlation between percent changes in left anterior descending artery (LAD) diameters from baseline values in response to intracoronary infusion
of 100 g acetylcholine (ACh) and 2-h insulin area, plasma lipid hydroperoxide (TBARS) level of coronary sinus-arterial (CS-Ao) difference,
BH4/7,8-BH2  biopterin, and dihydropteridine reductase (DHPR) activity in study subjects (n  36). BH4  tetrahydrobiopterin; BH2 
dihydrobiopterin.
Table 3. Multiple Stepwise Regression Analysis of Variables Significantly Associated With
Percent Changes of Acetylcholine-Induced Left Anterior Descending Artery Diameters
 SE F
Partial
R2 p Value
Model 1
TBARS (CS-Ao) 0.460 2.507 11.05 0.273  0.001
BH4/7,8-BH2  biopterin 0.345 3.204 6.19 0.115  0.001
Multiple R2  0.388
Model 2
TBARS (CS-Ao) 0.408 2.553 8.38 0.251  0.001
DHPR activity 0.379 677.7 7.20 0.116  0.001
Multiple R2  0.367
Model 3
DHPR activity 0.412 712.8 7.70 0.251  0.001
2-h insulin area 0.305 0.067 4.23 0.086  0.001
Multiple R2  0.337
Model 1 includes age, body mass index, mean blood pressure, cigarette-years, total cholesterol, 2-h glucose area, 2-h insulin area,
thiobarbituric acid reactive substances (TBARS) coronary sinus-descending aorta (CS-Ao) and (6R)-5,6,7,8-tetrahydrobiopterin
(BH4)/7,8-BH2  biopterin as independent variables. Model 2 includes age, body mass index, mean blood pressure,
cigarette-years, total cholesterol, 2-h glucose area, 2-h insulin area, TBARS coronary sinus-descending aorta (CS-Ao) and
dihydropteridine reductase (DHPR) activity as independent variables. Model 3 includes age, body mass index, mean blood
pressure, cigarette-years, total cholesterol, 2-h glucose area, 2-h insulin area and DHPR activity as independent variables.
  standardized regression coefficient; R  multiple correlation coefficient; SE  standard error.
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DISCUSSION
This study showed that responses of angiographically nor-
mal coronary arteries to ACh were impaired in subjects with
insulin resistance. Furthermore, not only decrements of the
plasma BH4/7,8-BH2 ratio and DHPR but also enhance-
ment of oxidative stress and defects of antioxidant defenses
were observed in these subjects. Conversely, ACh-induced
vasodilation was positively correlated with insulin sensitiv-
ity, BH4/7,8-BH2 ratio and DHPR activity. Thus, in
addition to overproduction of LPO in the coronary artery,
decreased BH4/7,8-BH2 ratio also appeared to be an inde-
pendent predictor of impaired epicardial vasodilator re-
sponses to ACh, suggesting that these factors exerted
additional adverse effects on the endothelial function of the
coronary artery. Moreover, the unaltered sensitivity to NTG
among the three different groups (Fig. 1) suggested that the
reactivity of smooth muscle cell per se was not significantly
altered and the abnormal pteridine levels were specific for
endothelium-dependent pathways in the insulin-resistant
state. All these findings are compatible with the hypothesis
that inactivation of NO through abnormal pteridine metab-
olism might be partly responsible for the impairment of
coronary vasodilation in patients with insulin resistance.
Insulin resistance and vascular oxidative stress. Several
lines of evidence now link excess vascular oxidative stress to
the impairment of NO action in subjects with insulin
resistance (2,5). We have previously reported that insulin
resistance causes oxidative stress to cardiovascular tissues
and the release of oxygen free radicals from endothelial cells
(11). Moreover, not only was there an increase in the LPO
level, but also marked activation of redox-sensitive tran-
scription factors in cardiovascular tissues of insulin-resistant
rats (12). In separate analyses, plasma levels of TBARS were
also significantly increased in patients with VSAP compared
with control subjects (control, 1.70  0.29; VSAP, 3.34 
0.53 nmol/ml, p  0.05). These findings suggest that
increased oxidative stress associated with insulin resistance
contributes to endothelial dysfunction in patients with
VSAP.
Pteridine metabolism and eNOS activity. Previous data
from our laboratory and other groups suggest abnormal pteri-
dine metabolism as a possible mechanism linking insulin
resistance to vascular disease (11,12). In vivo data suggest that
increased plasma BH4 levels can augment endothelial NO
production (22). Endothelial cells constitutively release sub-
stantial amounts of BH4 and neopterin (23). Neopterin is an
oxidized product of 7,8-dihydroneopterin-triphosphate, the
intermediate generated by GTP-CH1. The constancy of the
neopterin to biopterin ratio and total biopterin levels (Table 2)
suggest that the activity of GTP-CH1 is not decreased in the
insulin-resistant state. These results suggest that reduction in
the BH4/7,8-BH2 ratio rather than depletion of BH4 is
associated with impaired eNOS activity and thereby contrib-
utes to the defective ACh-induced vasodilation observed in
human insulin-resistant states. The plasma 7,8-BH2 levels in
IR subjects showed highly significant increases, suggesting that
the insulin-resistant state leads to increases in the synthesis of
BH2.
As illustrated in Figure 3, because BH4 is rapidly oxidized
to 7,8-BH2, a lack of sufficient DHPR activity would lead to
accumulation of 7,8-BH2, which has been shown to inhibit
the stimulatory effects of BH4 on NO synthase (24). In
addition, high concentrations of 7,8-BH2 inhibit GTP-
CH1 and hence de novo synthesis of BH4 (9). Therefore,
although it remains uncertain to what extent endothelial
cells are responsible for and/or are affected by these declines,
the present results support the hypothesis that insulin
resistance induces vascular dysfunction through alterations
in the BH4/7,8-BH2 ratio (14).
Potential mechanisms underlying the abnormal pteridine
metabolism in subjects with insulin resistance. It is
important to note that in the present study the BH4/7,8-
BH2 ratio and DHPR activity were significantly reduced in
patients with VSAP compared with subjects with chest pain
syndrome. The reason for this reduced BH4/7,8-BH2 ratio
is not clear. One possible cause is the increased production
of reactive oxygen species in the insulin-resistant state,
resulting in enhanced oxidation of BH4 to BH2 (25). In
agreement with other reports (5,6), coronary LPO produc-
tion emerged in our study as a stronger predictor of
endothelial dysfunction.
In the present study, DHPR activity was correlated with
the BH4/7,8-BH2 ratio. Interestingly, it has been reported
that physiological concentrations of glutathione increase the
synthesis and biological activity of NOS by activating
DHPR (26). Consistent with these results, administration
of either GSH or vitamin C improves the impairment of
endothelium-dependent vasodilation in patients with coro-
nary spastic angina (5,6). Although the multivariate analysis
was negative for cigarette smoking, higher cumulative to-
bacco consumption was correlated with lower BH4/7,8-
BH2 ratio and the maximal ACh-induced vasoconstriction.
Therefore, a high frequency of smokers among IR subjects
would be an explanation for decreased DHPR activity and
BH4/7,8-BH2 ratio. In this context, it is conceivable that
the abnormal intracellular redox state in the insulin-resistant
state, which is unfavorable for reduction of the oxidized
biopterin, impairs the endothelial recycling of BH4, and an
optimal ratio of BH4/7,8-BH2 is critical for eNOS activa-
tion.
Clinical usefulness and limitations of biopterin deriva-
tives as markers for vascular function. The interpretation
of changes in plasma and tissue biopterin derivative levels as
reflections of tissue contents of those derivatives remains
speculative in the present study. However, it has been
shown that when DHPR activity is decreased, more 7,8-
BH2 appears in the plasma, and the plasma 7,8-BH2 is low
when de novo synthesis of BH4 is low (27). Furthermore,
we have also reported that plasma and tissue biopterin levels
are closely associated with each other (12). These results
suggest that measurement of pteridines would provide a
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sensitive and informative measure of changes in the function
of vascular cells. Moreover, the hypothesis that patients with
abnormal pteridine metabolism are at increased risk of
developing cardiovascular disease, including high blood
pressure, VSAP, and atherosclerosis, must be further inves-
tigated.
Conclusions. Finally, the novel observation of this study is
that deranged endothelial responses to ACh in the insulin-
resistant state are, at least in part, due to impairments of the
NO system caused by abnormal pteridine metabolism and
vascular oxidative stress.
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